Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Clinical Trials

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

Phase 2

Completed

Conditions: Infection, Human Immunodeficiency Virus
HIV Infections

Interventions: Drug: Efavirenz 600 mg
Drug: GSK1265744 10 mg
Drug: GSK1265744 30 mg
Drug: GSK1265744 60 mg
Drug: Rilpivirine 25 mg
Drug: Placebo
Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)

First Posted Date: 2012-07-17

Last Posted Date: 2020-01-30

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 244

Registration Number: NCT01641809

Locations: 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada

BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection

Phase 2

Conditions: HIV

Interventions: Drug: efavirenz

First Posted Date: 2012-07-16

Last Posted Date: 2015-03-02

Lead Sponsor: PENTA Foundation

Target Recruit Count: 160

Registration Number: NCT01641016

Locations: 🇮🇪
Our Lady's Children's Hospital, Dublin, Ireland
🇹🇭
Program for HIV Prevention and Treatment (PHPT)/IRD 174, Changklan, Muang, Chiang Mai, Thailand
🇫🇷
INSERM, Villejuif, France

and more 15 locations

Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected

Phase 1

Completed

Conditions: HIV-1 Infection
Pf Subclinical Parasitemia

Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate
Drug: Lopinavir/ritonavir
Drug: Efavirenz
Drug: Nevirapine
Drug: Trimethoprim/sulfamethoxazole

First Posted Date: 2012-07-03

Last Posted Date: 2019-08-06

Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Target Recruit Count: 52

Registration Number: NCT01632891

Locations: 🇰🇪
AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601), Eldoret, Kenya
🇰🇪
Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501), Kericho, Kenya
🇲🇼
College of Med. JHU CRS (30301), Blantyre, Malawi

and more 2 locations

A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Doravirine
Drug: Efavirenz
Drug: TRUVADA®
Drug: Placebo for Efavirenz
Drug: Placebo for Doravirine

First Posted Date: 2012-07-02

Last Posted Date: 2019-07-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 342

Registration Number: NCT01632345

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Lamivudine/zidovudine
Drug: Raltegravir
Drug: Efavirenz

First Posted Date: 2012-06-13

Last Posted Date: 2020-01-30

Lead Sponsor: Westat

Target Recruit Count: 408

Registration Number: NCT01618305

Locations: 🇹🇭
Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand
🇹🇭
Bhumibol Adulyadej Hospital, Bangkok, Thailand
🇧🇷
Hospital Nossa Senhora da Conceicao NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil

and more 16 locations

A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: danoprevir
Drug: efavirenz
Drug: ritonavir

First Posted Date: 2012-04-30

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT01588002

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

Phase 4

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: Rilpivirine
Drug: Efavirenz

First Posted Date: 2012-04-25

Last Posted Date: 2015-08-14

Lead Sponsor: Indiana University

Target Recruit Count: 40

Registration Number: NCT01585038

Locations: 🇺🇸
Indiana Clinical and Translational Sciences Institute, Indianapolis, Indiana, United States

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: PA-824
Drug: Lopinavir/Ritonavir (LPV/r)
Drug: Efavirenz (EFV)
Drug: Rifampin (RIF)

First Posted Date: 2012-04-05

Last Posted Date: 2021-11-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 52

Registration Number: NCT01571414

Locations: 🇺🇸
Ucsf Hiv/Aids Crs, San Francisco, California, United States
🇺🇸
Johns Hopkins University CRS, Baltimore, Maryland, United States
🇺🇸
Ohio State University CRS, Columbus, Ohio, United States

and more 1 locations